You are in: eMedicine Specialties > Emergency Medicine > TRAUMA AND ORTHOPEDICS Ankle Injury, Soft TissueArticle Last Updated: Sep 13, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Christopher F Richards, MD, Adjunct Associate Professor, Department of Emergency Medicine, Oregon Health and Sciences University; Consulting Staff, Department of Emergency Medicine, St Charles Medical Center Christopher F Richards is a member of the following medical societies: American College of Emergency Physicians, Massachusetts Medical Society, and Society for Academic Emergency Medicine Editors: Edward Bessman, MD, Chairman, Department of Emergency Medicine, John Hopkins Bayview Medical Center; Assistant Professor, Department of Emergency Medicine, Johns Hopkins University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Tom Scaletta, MD, President, American Academy of Emergency Medicine; Chairperson, Department of Emergency Medicine, Edward Hospital; Assistant Professor of Emergency Medicine, Rush Medical College/Cook County Hospital; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital Author and Editor Disclosure Synonyms and related keywords: ankle injury, soft tissue ankle injury, soft-tissue ankle injury, ankle sprain, sprained ligament, twisted ankle, Ottawa ankle rules, sports-related ankle injury, ankle injuries, anterior talofibular ligament rupture, ATFL rupture, recurrent ankle sprain, calcaneofibular ligament rupture, CFL rupture, posterior talofibular ligament rupture, PTFL rupture, distal tibiofibular syndesmotic rupture, superior peroneal retinaculum rupture, ankle ligaments, inversion ankle injury INTRODUCTIONBackgroundAnkle injuries are the most common injuries incurred during sports and recreational activities. They are particularly common in sports such as basketball, soccer, volleyball, or other activities performed on uneven surfaces. PathophysiologyMost ankle sprains are due to inversion during extension (plantarflexion) of the ankle. Thus, approximately 85% of injuries involve the 3 distinct lateral ligaments: anterior talofibular ligament (ATFL), calcaneofibular ligament (CFL), and posterior talofibular ligament (PTFL). Of sprains due to inversion, 65% are isolated to the ATFL. In some patients, the subtalar complex may also be injured. The CFL is rarely injured in isolation. Isolated injury to the medial (deltoid) ligament is rare and usually involves malleolar fractures. Distal tibiofibular syndesmotic rupture is very rare and is associated with flexion (dorsiflexion) and external rotation. Recovery from this injury is significantly prolonged, unlike isolated lateral ligament sprains. Mild syndesmotic sprains are increasingly being recognized and are probably more common than previously thought. Rupture of the superior peroneal retinaculum results in subluxation or dislocation of the peroneal tendons. The mechanism of injury is usually forced dorsiflexion with reflex contraction of the peroneal muscles. Patients complain of pain and a snapping sensation over the posterolateral ankle with weakness of eversion. Ankle sprains are classified into 3 grades per the West Point Sprain Grading System, as follows:
FrequencyUnited StatesInversion injuries occur at a rate of 1 per 10,000 people per day, which is about 2,800 injuries per day in the United States. Injury to the dominant ankle is 2-3 times more likely than injury to the nondominant ankle. Mortality/Morbidity
SexWomen athletes are 25% more likely to sustain ankle injuries than male athletes. AgeAnkle injuries primarily involve young people because they participate more often in physically demanding recreational activities and sports. Fractures and tendon ruptures occur more often in older adults. CLINICALHistory
Physical
DIFFERENTIALSFractures, Ankle Fractures, Foot Tendonitis Tenosynovitis
|
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) |
|---|---|
| Description | Usually DOC for treatment of mild to moderate pain, if no contraindications exist. Inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, resulting in the inhibition of prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 20-40 mg/kg/d PO divided tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) |
|---|---|
| Description | Used for the relief of mild to moderate pain and inflammation. Administer small doses initially to patients with small body size, elderly patients, and those with renal or liver disease. Doses higher than 75 mg do not increase its therapeutic effects. Administer high doses with caution, and closely observe patients for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1–1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Anaprox, Naprelan, Naprosyn) |
|---|---|
| Description | For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg PO q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and enable physical therapy regimens. Many analgesics have sedating properties that are beneficial for patients who have sustained injuries.
| Drug Name | Acetaminophen (Tylenol, Panadol, Aspirin-Free Anacin) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking oral anticoagulants. |
| Adult Dose | 325-650 mg PO q4-6h or 1,000 mg tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses/d |
| Contraindications | Documented hypersensitivity; known G-6-PD deficiency |
| Interactions | Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Hepatotoxicity possible in chronic alcoholics following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative doses exceeding recommended maximum dose |
| Drug Name | Acetaminophen and codeine (Tylenol #3) |
|---|---|
| Description | Drug combination indicated for the treatment of mild to moderate pain. |
| Adult Dose | 30-60 mg/dose based on codeine content PO q4-6h or 1-2 tab PO q4h; not to exceed 12 tab/d |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity of codeine increases with CNS depressants, tricyclic antidepressants, MAO inhibitors, neuromuscular blockers, CNS depressants, phenothiazines, and narcotic analgesics Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity of acetaminophen |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Hydrocodone bitartrate and acetaminophen (Vicodin ES) |
|---|---|
| Description | Drug combination indicated for moderate to severe pain. |
| Adult Dose | 1-2 tab PO q4-6h prn pain |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d of acetaminophen >12 years: 750 mg acetaminophen PO q4h; not to exceed 5 doses/d; single dose should not exceed 10 mg of hydrocodone bitartrate |
| Contraindications | Documented hypersensitivity; high-altitude cerebral edema (HACE); elevated intracranial pressure (ICP) |
| Interactions | Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
Ankle Injury, Soft Tissue excerpt
Article Last Updated: Sep 13, 2007